Dual RAAS suppression: Recent developments and implications in light of the ALTITUDE study

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 3, 2012, Pages 409-412

  De Boer, Rudolf A ^a   Azizi, Michel ^b   Danser, A H Jan ^c   Nguyen, Geneviève ^d   Nussberger, Jürg ^e   Ruilope, Luis M ^f,g   Schmieder, Roland E ^h   Volpe, Massimo ⁱ  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Centre for Interdisciplinary Research in Biology (CIRB)   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Universidad Autonoma   (Spain)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN;

ACUTE HEART FAILURE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEFT VENTRICULAR ASSIST DEVICE; NONHUMAN; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; STROKE; SYNCOPE; TREATMENT OUTCOME;

EID: 84865636322     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312455271     Document Type: Article

References (15)

1. Introducing the RAAS Working Group. J RAAS. 2010 ; 12: 123
2. U.S. Food and Drug Administration. FDA Drug Safety Communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna), http://www.fda.gov/drugs/drugsafety/ucm300889.htm (accessed 28 April 2012).
3. Richer-Giudicelli C, Domergue V, Gonzalez M-F, et al. Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J Hypertens. 2004 ; 22: 619-627 (Pubitemid 38368497)
4. Danser AHJ, van Kesteren CAM, Bax WA, et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation. 1997 ; 96: 220-226 (Pubitemid 27298424)
5. Klotz S, Burkhoff D, Garrelds IM, et al. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?. Eur Heart J. 2009 ; 30: 805-812
6. Volpe M, Tocci G, Bianchini F, et al. Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens. 2012 ; 30: 194-203
7. Volpe M, Danser AHJ, Ménard J, et al. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?. J Hypertens. 2012 ; 30: 647-654
8. Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One. 2010 ; 5: e9946
9. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J. 2010 ; 31: 2205-2208
10. Schroten NF, Gaillard CA, van Veldhuisen DJ, et al. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev. 2012 ; 17: 191-201
11. Szymanski MK, Damman K, van Veldhuisen DJ, et al. Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. Am Heart J. 2011 ; 162: 487-493
12. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 ; 1: 17-24
13. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 ; 32: 1227-1234
14. McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012 ; 14: 341-343
15. Azizi M, Ménard J. Renin inhibitors and cardiovascular and renal protection: an endless quest?. Cardiovasc Drugs Ther. :